Janney Montgomery Scott LLC Purchases 2,897 Shares of Exelixis, Inc. (NASDAQ:EXEL)

Janney Montgomery Scott LLC grew its position in Exelixis, Inc. (NASDAQ:EXEL) by 9.5% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 33,296 shares of the biotechnology company’s stock after buying an additional 2,897 shares during the period. Janney Montgomery Scott LLC’s holdings in Exelixis were worth $1,109,000 at the end of the most recent quarter.

A number of other large investors have also made changes to their positions in EXEL. MassMutual Private Wealth & Trust FSB increased its holdings in shares of Exelixis by 18.1% in the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 1,890 shares of the biotechnology company’s stock worth $63,000 after acquiring an additional 290 shares in the last quarter. Covestor Ltd increased its stake in Exelixis by 5.7% during the 3rd quarter. Covestor Ltd now owns 6,335 shares of the biotechnology company’s stock worth $164,000 after purchasing an additional 341 shares in the last quarter. UMB Bank n.a. raised its holdings in Exelixis by 68.4% during the 4th quarter. UMB Bank n.a. now owns 1,361 shares of the biotechnology company’s stock worth $45,000 after buying an additional 553 shares during the period. Advisors Asset Management Inc. lifted its stake in Exelixis by 3.2% in the third quarter. Advisors Asset Management Inc. now owns 19,853 shares of the biotechnology company’s stock valued at $515,000 after buying an additional 609 shares in the last quarter. Finally, Signaturefd LLC boosted its holdings in shares of Exelixis by 12.2% in the third quarter. Signaturefd LLC now owns 6,138 shares of the biotechnology company’s stock valued at $159,000 after buying an additional 666 shares during the period. Institutional investors own 85.27% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on EXEL. TD Cowen raised their price objective on shares of Exelixis from $27.00 to $34.00 and gave the stock a “buy” rating in a report on Monday, October 21st. JMP Securities reissued a “market outperform” rating and issued a $41.00 price target on shares of Exelixis in a research note on Thursday, January 23rd. Wells Fargo & Company boosted their price target on Exelixis from $32.00 to $36.00 and gave the company an “overweight” rating in a report on Wednesday, October 30th. Piper Sandler lifted their target price on Exelixis from $36.00 to $37.00 and gave the company an “overweight” rating in a research report on Monday, January 13th. Finally, The Goldman Sachs Group raised Exelixis to a “strong sell” rating in a research report on Tuesday, October 15th. One equities research analyst has rated the stock with a sell rating, seven have issued a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $36.06.

Exelixis Stock Up 1.3 %

Shares of NASDAQ EXEL opened at $33.55 on Thursday. The business’s 50 day moving average price is $34.50 and its two-hundred day moving average price is $30.35. The company has a market cap of $9.58 billion, a PE ratio of 21.51, a price-to-earnings-growth ratio of 0.72 and a beta of 0.53. Exelixis, Inc. has a twelve month low of $20.01 and a twelve month high of $37.59.

Insider Transactions at Exelixis

In related news, EVP Patrick J. Haley sold 41,588 shares of Exelixis stock in a transaction dated Monday, November 18th. The shares were sold at an average price of $34.36, for a total transaction of $1,428,963.68. Following the completion of the sale, the executive vice president now owns 288,665 shares of the company’s stock, valued at approximately $9,918,529.40. The trade was a 12.59 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, EVP Jeffrey Hessekiel sold 60,000 shares of the company’s stock in a transaction dated Friday, November 29th. The shares were sold at an average price of $36.67, for a total transaction of $2,200,200.00. Following the completion of the transaction, the executive vice president now owns 486,059 shares in the company, valued at approximately $17,823,783.53. This trade represents a 10.99 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 111,588 shares of company stock worth $3,981,864. 2.85% of the stock is owned by company insiders.

Exelixis Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.